Last reviewed · How we verify
Monacrin (aminoacridine)
Monacrin (generic name: aminoacridine) is a aminoacridine drug. It is currently in unknown development.
Monacrin works by inhibiting the activity of Ribosyldihydronicotinamide dehydrogenase [quinone], an enzyme that plays a crucial role in cellular energy production.
Monacrin is a small molecule with the synonym 9-Aminoacridine. It is one of several chemical compounds known as aminoacridines, which include 2-Aminoacridine, 3-Aminoacridine, and 4-Aminoacridine.
At a glance
| Generic name | aminoacridine |
|---|---|
| Drug class | aminoacridine |
| Target | Ribosyldihydronicotinamide dehydrogenase [quinone], Amine oxidase [flavin-containing] A, Trypanothione reductase |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of it like a car engine: Ribosyldihydronicotinamide dehydrogenase [quinone] is like the fuel pump that helps generate energy for the cell. Monacrin is like a brake that slows down the fuel pump, reducing the cell's energy production. This can be beneficial in certain situations, but it also means the cell may not be able to function properly.
Approved indications
Common side effects
Key clinical trials
- Comparing Dual-mobility Cups Versus Unipolar Cups for Unselected Primary Total Hip Arthroplasty by Direct Anterior Approach (NA)
- Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States (PHASE2)
- Precision Optical Guidance for Oral Biopsy (NA)
- Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery (NA)
- Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders (EARLY_PHASE1)
- The Effectiveness of High Resolution Microendoscopy for People Living With HIV (PHASE1,PHASE2)
- Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia (PHASE3)
- Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monacrin CI brief — competitive landscape report
- Monacrin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Monacrin
What is Monacrin?
How does Monacrin work?
What is the generic name of Monacrin?
What drug class is Monacrin in?
What development phase is Monacrin in?
What does Monacrin target?
Related
- Drug class: All aminoacridine drugs
- Target: All drugs targeting Ribosyldihydronicotinamide dehydrogenase [quinone], Amine oxidase [flavin-containing] A, Trypanothione reductase
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing